Recent studies have indicated that non-coding RNAs transcribed from enhancer regions are important regulators of enhancer function and gene expression. In this report, we have characterised the expression of six enhancer RNAs (eRNAs) induced in human monocytic THP1 cells following activation of the innate immune response by lipopolysaccharide (LPS). Specifically, we have demonstrated that LPS-induced expression of individual eRNAs is mediated through divergent intracellular signalling pathways that includes NF-κB and the mitogen activated protein kinases, extracellular regulated kinase-1/2 and p38.

© 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Cells of the innate immune response, including circulating monocytes, prevent infection through the rapid removal of invading pathogens [1]. Monocytes are able to detect micro-organisms by a variety of mechanisms including the use of membrane associated pattern recognition receptors (PRR) that bind to conserved components upon the pathogens. The best described is the Toll-like receptor (TLR) family and in particular TLR4, which is activated by lipopolysaccharide (LPS), a component of gram-negative bacteria cell walls. TLR4 activation triggers intracellular signalling cascades, most notably those that lead to activation of the transcription factor, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). In addition, LPS stimulation has been shown to stimulate multiple mitogen activated protein kinase (MAPK) signalling pathways including extracellular signal-regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNK1/2) and p38 MAPK [2]. This ultimately results in the activation of additional transcription factors involved in the antimicrobial response including activator protein (AP-1) and cAMP-responsive-element-binding protein 1 (CREB1) [3].

One of the mechanisms by which the expression of individual genes can be potentially regulated by transcription factors is through interaction with enhancers, regulatory regions of the genome distally located from protein coding genes [4]. This is thought to result in the looping of the chromatin structure which brings the enhancer region into close proximity with the promoters of regulated genes [5,6]. Interestingly, recent studies have indicated that the action of enhancers is dependent upon the transcription of non-coding RNAs, entitled enhancer RNAs (eRNAs) [7]. These are involved both in the establishment of enhancer sites and in the subsequent looping and regulation of gene expression in cis [8–13].

In previous reports, ourselves [13] and other investigators [14] have identified widespread induction of eRNAs following activation of the innate immune response. In this report, we have characterised the expression of a range of eRNAs that are induced in response to LPS stimulation of monocytic THP-1 cells. Since little is known about the signalling pathways that regulate the production of these immune-related eRNAs, we have examined the role of NF-κB and the MAPK intracellular pathways and shown that the expression of eRNAs is regulated by multiple divergent mechanisms.

2. Materials and methods

2.1. Culture of human monocytic THP-1 cells

Monocytic THP-1 cells were cultured in RPMI 1640, supplemented with 10% (v/v) FBS, 1-glutamine (2 mM), 1% (v/v) Pen-Strep...
and 0.1% (v/v) β-mercaptoethanol (Invitrogen Gibco) and cultured in a 37°C, 5% (v/v) CO₂ humidified incubator.

2.2. Stimulation and drug treatment of monocytic THP-1 cells

Monocytic THP-1 cells were seeded at 5 × 10⁵ cells/well in 500 µl in 24 well plates. Cells were treated with media or 1 µg/ml LPS (Escherichia coli 055:B5, Sigma Aldrich) for 0–24 h (n = 3/group/time-point). For the TLR agonist experiment, cells were treated with PAM3CSK4 (100 ng/ml), HKLM (10⁵ cells/ml), poly(I:C) (10 mg/ml), poly(I:C) LMW (10 mg/ml), Flagellin (100 ng/ml), FSL-1 (100 ng/ml), Imiquimod (5 µg/ml), ssRNA40 (1 µg/ml) and ODN2006 (2 µM) (all from InvivoGen). In addition, THP-1 cells were also treated with buffer (control), LPS and IL-1β (10 ng/ml, recombinant, E. coli, Sigma Aldrich). For drug treatments, cells were incubated with DMSO (vehicle control) or 0.1–10 µM of TPCA-1 (IkB kinase-2 inhibitor, Sigma–Aldrich), PD0325901 (MEK inhibitor, Tocris) and SCIO 469 (p38 inhibitor, Tocris) for 30 min, prior to stimulation with LPS for 4 h.

2.3. RNA isolation and cDNA synthesis

Total RNA was extracted using the Qiagen RNeasy kit which included an on-column DNase treatment. cDNA was synthesised using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems).

2.4. qRT-PCR quantification of RNA expression

Expression of eRNAs, mRNAs and 18S RNA was determined by qRT-PCR using the SYBR® Green PCR mix (Applied Biosystems). The separate well, 2⁻¹(DDCt) method was used to determine relative-quantities of individual mRNAs and eRNAs which were normalised to 18S RNA. Primers used are listed in Table 1.

2.5. Nuclear-cytoplasm RNA fractionation

Monocytic THP-1 cells were stimulated with LPS for 2 h or 6 h. The cells were centrifuged and then split into two equal fractions. Total RNA was extracted from one fraction using the normal Qiagen RNeasy protocol whilst the other fraction was treated with RNA buffer on ice for 5 min, in order to lyse the plasma membrane whilst leaving the nuclei intact. The nuclei were then isolated by centrifugation at 3000 g in a pre-chilled centrifuge. RNA was extracted from the nuclear and cytoplasm fractions using the normal Qiagen RNeasy protocol. In order to quantify gene expression within the different fractions by qRT-PCR, the 18S values from the total RNA fraction were used to normalise the data.

2.6. Transfection of monocytic THP-1 cells with anti-p65 siRNAs

Monocytic THP-1 cells were seeded at 2.5 × 10⁵ cells/well in 24 well plates, in 100 µl of complete growth medium. Transfection mixes were prepared using 95 µl of serum-free growth medium, 5 µl of HiPerFect (QIAGEN) plus siRNAs to give a final concentration of 30 nM. Cells were subsequently incubated for 6 h, diluted with 400 µl of complete growth medium, incubated for a further 42 h and then stimulated with LPS for 2 h. siRNA sequences are listed in Table 1.

2.7. Detection of p65 and MAP kinases using Western blotting

Monocytic THP-1 cells were seeded at 1.5 × 10⁶ cell/well in 12 well plates and transfected with siRNAs (see above). Cells were lysed in buffer containing 50 mM Tris–HCl, 150 mM NaCl, 1% (v/v) Nonidet P40, 1 mM sodium vanadate, 1 mM sodium molybdate, 10 mM sodium fluoride, 40 µg/ml PMSF, 0.7 µg/ml pepstatin A, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 10 µg/ml soybean trypsin inhibitor. Lysed samples were subsequently diluted in sam-

---

Table 1

Sequences of qRT-PCR primers and siRNAs.

| Primers | Forward primer | Reverse primer |
|---------|----------------|----------------|
| 18S RNA | AAACCGCCTACCACTCCAAG | CTCCTAATGATCTTCTCGTTA |
| IL6     | ACTCATCTCTCAGAAGGACTT  | CCAATCTGGAAGGCATTGGT |
| p65     | GTCCGCTTGGGCCGTCATCTG  | GGGCGAGGAATGGGTCGAG |
| MALAT1  | CTAAGGAGCCACCATTATT   | GGGACGAGCTTAAGGACACC |
| MT-CYB  | TAGACGCTCACCCTCATTACA  | CTTGCGAAAAGTGATACCC |
| MARCKS-eRNA | CACACCAGAAGATGCTGAA | GCCCACTGACCAGTACAC |
| ACSL1-eRNA | ACCATCGCAAGATGCTGAA  | CCTCCCTAAGGAGTTCC |
| AZIN1-eRNA | GGGACTGCTGCGTCACTGG  | CCAACCAGGAGCGATACAG |
| TNFSF8-eRNA | TCTCCCTCCTAAGTGTTGTT | CACACAGGAGGGATACAG |
| SLC30A4-eRNA | GTGATGTGACAGCGTACGGCA | ACTCTTCTTGGGTTGGGAG |
| SOCS3-eRNA | TGTTGGTGGAGACACTCTGGGC  | CTTGCTCTTCTACGCGGG |
| CHIP    | Forward primer     | Reverse primer |
| SOD2    | CCCTGTACATGATGGTGCCT  | GGGAAAAGGCGCGCGTATT |
| IL6     | AAAGGTCACACATCACCAC  | CTTGATGCGGCTGTTTA |
| SLC30A4-eRNA | TTTTGCCGCTTCCTGTTT   | GGCATCTTCCTACGAC |
| SOCS3-eRNA | TCTGAACACCTGGTCTGCC  | CACCTCTGGCCGCTATAC |
| AZIN1-eRNA | AGGTTACGCTTGGTCTTTATTG  | GGCAAAACKCATTACGTAGT |
| TNFSF8-eRNA | GATGACATGCTGACGCCCA  | AGGAGGGAAGGCAATAT |
| MARCKS-eRNA | CACACCCCAAGATGCTGAA  | GGCATCTTCCTATTTCGTA |
| ACSL1-eRNA | GGGAAGGGACACCTGCTGG  | CTTCTGACGTCACAGGAG |

| siRNAs | Sequence | Source |
|--------|----------|--------|
| Scrambled | UGGGCUUAACAUUGGCUACUA | Dharmacon |
| Anti-p65 1 | GCAGUUGGAGCAAAUUGGUA | Dharmacon |
| Anti-p65 2 | CCACCAGCUUGUUGAGAA | Dharmacon |
ple buffer containing 5% β-mercaptoethanol, boiled and then separated by electrophoresis on a 10% SDS–PAGE gel. Proteins were transferred to a nitrocellulose membrane and probed with rabbit anti-p65 (NF-κB p65, C-20, Santa Cruz), rabbit anti-pERK-1/2, p-p38, ERK-1/2 and p38 (Phospho-MAPK Family Antibody and MAPK Family Antibody Sampler kit, Cell Signaling) or rabbit anti-GAPDH (D16H11, Cell Signaling Technology). The membranes were subsequently incubated with HRP-conjugated goat anti-rabbit secondary antibody (DAKO) and bands visualised using an EZ-ECL chemiluminescence detection kit (Geneflow, Staffordshire, UK) and Image-Quant developer (GE healthcare, Buckinghamshire, UK).

2.8. Chromatin Immunoprecipitation

Chromatin immunoprecipitation (ChIP) was performed according to the manufacturer’s guidelines (Active Motif; 53040). In brief, 3 × 10⁷ THP1 cells were stimulated or not with LPS (1 μg/ml) for 60 min. Whole cells were cross-linked with a 1% formaldehyde solution for 15 min at room temperature. Cells were sonicated (Branson Sonifier 250) for 2 cycles (output: 1, duty cycles: 20%, time: 30 s on 30 s off). DNA concentrations were quantified, and 10 μl of chromatin DNA was used for each ChIP reaction. ChIP assays were performed with 4 μg of antibody (NF-κB p65, C-20, Santa Cruz) and incubated overnight at 4°C, precipitated with agarose beads (supplied) and washed. Bead-bound DNA was reverse cross-linked and purified with DNA Purification columns (supplied). Samples were then analysed by qPCR using the probes listed in Table 1.

3. Results

3.1. eRNAs are differentially expressed following LPS stimulation

In a previous publication, we used RNA-seq to interrogate the transcriptome of control and LPS stimulated human monocytes and identified 76 multi-exonic, mono-directionally transcribed eRNAs that were regulated by LPS plus 35 bi-directionally transcribed eRNAs [13]. eRNAs were defined as having a high H3K4me1/H3K4me3 ratio in line with previous reports [15] and annotated according to the nearest expressed protein coding gene.

Table 2

| Gene           | p65 | JUN | FOS | JUND | FANTOM enhancer |
|----------------|-----|-----|-----|------|-----------------|
| ACSL1 eRNA     | 5 (0)| 2 (0)| 7 (0)| 4 (1)| 3 (0)           |
| MARCKS eRNA    | 5 (0)| 1 (0)| 4 (0)| 4 (0)| 7 (0)           |
| AZIN1 eRNA     | 1 (0)| 0 (0)| 1 (0)| 0 (0)| 2 (0)           |
| TNSF58 eRNA    | 3 (1)| 2 (0)| 3 (1)| 3 (0)| 4 (1)           |
| SLC30A4 eRNA   | 1 (0)| 1 (0)| 4 (1)| 3 (0)| 4 (0)           |
| SOCS3 eRNA     | 3 (0)| 0 (1)| 1 (1)| 1 (2)| 1 (1)           |
| IL6            | 0 (1)| 2 (3)| 1 (1)| 2 (0)| 0 (0)           |
| SOD2           | 2 (1)| 0 (1)| 1 (2)| 2 (3)| 0 (0)           |

Fig. 1. Example of immune-regulated eRNA in monocytic THP-1 cells. eRNAs genes are demarcated by high H3K4me1 and expressed co-ordinately with neighbouring genes. ACSL1 is an example of a protein coding gene with an upstream eRNA gene, both of which are upregulated upon LPS stimulation. RNA-seq data from control (red) and LPS stimulated (blue) monocytes are displayed in the top two tracks. The middle two panels display ChIP-seq data from human monocytes indicating the methylation status of H3K4, with H3K4me1 (enhancer mark) displayed in orange and H3K4me3 (promoter mark) in green. The bottom panel displays transcription factor binding sites identified in the ENCODE project [23], transcribed enhancers identified in the FANTOM project [16] and gene annotations for ACSL1 from RefSeq (blue) and ACSL1-eRNA (black; [13]). Figure produced using the UCSC genome browser.
e.g. IL1β-eRNA. The LPS-regulated eRNAs displayed co-ordinated expression with neighbouring genes, the majority of which were associated with the inflammatory response. An example of an LPS-induced eRNA neighbouring and co-expressed with the gene long-chain acyl-CoA synthetase (ACSL) 1, is shown in Fig. 1. ACSL1 esterifies long chain fatty acids, a preliminary step in the biogenesis of lipid mediators including the pro-inflammatory prostaglandin E2. ACSL1-eRNA, ~10 kb upstream of ACSL1, overlapped with the binding sites of multiple transcription factors shown previously to regulate the inflammatory response, including sub-units of NF-κB (RelA/p65) and AP-1 (c-fos, c-jun) [2]. In addition, ACSL1-eRNA overlapped with enhancer regions recently classified by the FANTOM project [16]. The overlap between transcription factor binding sites and the enhancer regions characterised by the FANTOM project was also observed with five other eRNAs: SLC30A4-eRNA, SOCS3-eRNA, AZIN1-eRNA, TNFSF8-eRNA and MARCKS-eRNA (Table 2).

3.2. eRNA expression rapidly peaks following LPS stimulation of THP-1 monocytic cells

To begin to characterise eRNA expression, we initially examined the time course of LPS-induced expression of two key inflammatory genes, SOD2 and IL6 [17–19] and the six immune-related eRNAs, SLC30A4-eRNA, SOCS3-eRNA, AZIN1-eRNA, TNFSF8-eRNA, MARCKS-eRNA and ACSL1-eRNA. As expected, we observed a rapid

Fig. 2. Time course of LPS-induced mRNA and eRNA expression. Human monocytic THP-1 cells were exposed to either buffer or 1 μg/ml LPS for the indicated period of time prior to quantification of (a) IL6 and SOD2 mRNA and (b) SLC30A4-eRNA, SOCS3-eRNA, AZIN1-eRNA, TNFSF8-eRNA, MARCKS-eRNA and ACSL1-eRNA by qRT-PCR. Data is the mean ± S.E.M. of 3 independent experiments.
induction of SOD2 that peaked at 6 h and a steady increase in IL6 expression throughout the 24 h period (Fig. 2a). All of the eRNAs demonstrated rapid induction with expression peaking between 2 h and 6 h (Fig. 2b).

3.3. eRNA expression is induced by TLR4 and TLR6/2 receptor activation

We next determined the profile of expression following activation of other members of the TLR family (TLR1-9), as well as the inflammatory cytokine IL-1β. Both the inflammatory markers and the eRNAs displayed a similar expression profile, with significant expression only seen in response to LPS (TLR4 agonist) and FSL-1, which acts through the TLR6/2 heterodimer (Fig. 3). Although this needs to be investigated further, it is likely that the latter response is mediated predominantly via TLR6, since the TLR2 agonist (HKLM) had no significant action (Fig. 3).

3.4. LPS-induced eRNA expression is predominantly restricted to the nucleus

We next sought to determine whether the expression of LPS-induced eRNAs was restricted to the nucleus, consistent with their purported role as regulators of transcription [8,20,21]. To this end, control and LPS stimulated monocytic THP-1 cells were subjected to subcellular fractionation and RNA expression relative to whole cells was examined by qRT-PCR. Successful subcellular fractionation was confirmed following the observation that the nuclear

**Fig. 3.** Profile of mRNA and eRNA expression in response to exposure to TLR agonists and IL-1β. Human monocytic THP-1 cells were exposed to buffer, a range of TLR agonists or IL-1β for 2 h. TLR agonists included the synthetic bacterial lipoprotein (Pam3CSK4 acting via TLR-1/2), a heat-killed preparation of the gram-positive bacterium Listeria monocytogenes (HKLM acting via TLR-2), synthetic mimics of double stranded RNA (polyIC and polyIC LMW acting via TLR-3), the bacterial flagellin protein (acting via TLR-5), a synthetic lipoprotein derived from Mycoplasma salivarium (FSL-1 acting via TLR-2/6), an imidazoquinoline amine analog to guanosine (Imiquimod acting via TLR-7), a G-U rich single stranded RNA (ssRNA40 acting via TLR-8) and a CpG containing oligonucleotide (ODN2006 acting via TLR-9). Expression of (a) IL6 and SOD2 mRNA and (b) SLC30A4-eRNA, SOCS3-eRNA, AZIN1-eRNA, TNFSF8-eRNA, MARCKS-eRNA and ACSL1-eRNA was quantified by qRT-PCR. Data is the mean ± S.E.M. of 3 independent experiments. Statistical significance was determined using a one way ANOVA with a Dunnett’s post-test, where *P < 0.05, **P < 0.01 and ***P < 0.001.
Fig. 4. Subcellular distribution of mRNA and eRNA expression. Human monocytic THP-1 cells were stimulated with LPS for 2 h or 6 h prior to RNA extraction from either total cells or the nuclear and cytoplasm fractions. qRT-PCR was then used to analyse the expression and distribution, relative to a total cell fraction, of (a) IL6 and SOD2 mRNA and (b) SLC30A4-eRNA, SOCS3-eRNA, AZIN1-eRNA, TNFSF8-eRNA, MARCKS-eRNA, and ACSL1-eRNA by qRT-PCR. Data is the mean ± S.E.M. of 3 independent experiments.
located long non-coding RNA MALAT1 (metastasis associated lung adenocarcinoma transcript 1) [22] and mitochondrial mRNA MT-CYB (mitochondrially encoded Cytochrome B) was restricted to the nuclear and cytoplasmic fractions, respectively (data not shown see Ref. [13]). As supported by the time course data (Fig. 2a), IL6 expression was found to be equally distributed between the cytoplasm and nucleus, implying on-going transcription whilst SOD2 was predominant located in the cytoplasm (Fig. 4a). In the case of the eRNAs, 4 (SLC30A4-eRNA, SOCS3-eRNA, AZIN1-eRNA and TNFSF8-eRNA) demonstrated strong nuclear enrichment whilst MARCKS-eRNA and ACSL1-eRNA were expressed in both fractions (Fig. 4b).

3.5. LPS-induced eRNA expression is regulated by the NF-κB signalling pathway

Following the activation of TLR4, a number of signalling pathways including those that act through IKK2 (upstream activator of NF-κB) and members of the MAP kinase families are thought to regulate inflammatory gene expression via activation of transcription factors [2]. We therefore sought to determine whether these signalling pathways might also regulate LPS-induced eRNA expression through the use of pharmacological inhibitors.

The role of IKK2 upon the LPS-induced response at 4 h was initially examined using the pharmacological inhibitor, TPCA-1. As expected, the LPS-induced SOD2 and IL6 expression was repressed with IC50 values of 2.7 μM and 0.27 μM, respectively (Fig. 5). Interestingly, all of the LPS-induced eRNAs were significantly repressed following inhibition of IKK2, with IC50 values ranging from 0.083 μM (TNFSF8-eRNA) to 3.24 μM (SOCS3-eRNA) (Fig. 6). It was not possible to determine an IC50 value for ACSL1-eRNA, as only the highest concentration of TPCA-1 inhibited its expression.

To provide additional evidence of a role for NF-κB in LPS-induced eRNA expression we undertook studies using siRNA-mediated knockdown and chromatin immunoprecipitation (ChIP) in combination with qRT-PCR. Using two siRNAs targeted to the p65

![Fig. 5. Pharmacological analysis of the signalling pathways that regulate LPS-induced SOD2 and IL6 mRNA expression. Human monocytic THP-1 cells were treated with DMSO (vehicle control) or pharmacological inhibitors of IKK2 (TPCA-1), MEK (PD0325901) and p38 (SCIO 469) for 30 min prior to LPS stimulation (4 h). IL6 and SOD2 expression was quantified by qRT-PCR. Data is the mean ± S.E.M. of 3 independent experiments. Statistical significance was determined using a one way ANOVA with a Dunnett’s post-test, where *P < 0.05, **P < 0.01 and ***P < 0.001.](image1)

![Fig. 6. Pharmacological analysis of the signalling pathways that regulate LPS-induced eRNA expression. Human monocytic THP-1 cells were treated with DMSO (vehicle control) or pharmacological inhibitors of IKK2 (TPCA-1), MEK (PD0325901) and p38 (SCIO 469) for 30 min prior to LPS stimulation (4 h). SLC30A4-eRNA, SOCS3-eRNA, AZIN1-eRNA, TNFSF8-eRNA, MARCKS-eRNA and ACSL1-eRNA expression was quantified by qRT-PCR. Data is the mean ± S.E.M. of 3 independent experiments. Statistical significance was determined using a one way ANOVA with a Dunnett’s post-test, where *P < 0.05, **P < 0.01 and ***P < 0.001.](image2)
subunit of NF-κB we showed a significant decrease in the mRNA expression and protein level of p65, whereas no knockdown was observed following transfection with the negative control siRNA (Fig. 7a). Knockdown of p65 by both siRNAs significantly reduced the LPS-induced mRNA levels of SOD2 and IL6 (Fig. 7b). Similarly, the LPS-induced expression of all of the eRNAs was also impaired. Thus, significant decreases in LPS-induced expression of AZIN1-eRNA, TNFSF8-eRNA, MARCKS-eRNA and ACSL1-eRNA were observed although the decreases in LPS-induced expression of SLC30A4-eRNA and SOCS3-eRNA did not reach significance (Fig. 7c). Chromatin immunoprecipitation (ChIP) using an antibody to the p65 RelA DNA binding, was employed to measure NF-κB activation and binding in the absence and presence of IKK2 inhibitor. Although this only reached significance in 50% of the genes examined, these studies showed a general trend for increased NF-κB binding within the predicted promoter regions of SOD2, SLC30A4-eRNA, AZIN1-eRNA, SOCS3-eRNA, TNFSF8-eRNA and ACSL1-eRNA and that this was reversed in the presence of the IKK2 inhibitor (Fig. 8). In contrast, we observed no NF-κB binding in the promoter region of IL6 or MARCKS-eRNA (Fig. 8). The reasons for the variability in the ChIP studies is unclear although it could relate to a number of factors including the difficulties in predicting the NF-κB binding region (for qRT-PCR probe design) and the transient nature of NF-κB binding. Overall, this data suggested that the NF-κB signalling pathway has a key role in regulating LPS-induced eRNA expression.

3.6. LPS-induced eRNA expression is regulated by the MAP kinase signalling pathways

Using Western blotting, we were able to demonstrate activation of the ERK-1/2 and p38 using phosphoantibodies to detect the activation forms of these MAP kinases (Fig. 9). Importantly, following
the observation that this phosphorylation/activation could be completed attenuated in the presence of the selective MEK-1/2 (PD0325901) and p38 (SCIO 469) inhibitors (Fig. 9), these compounds were employed to examine the role of these pathways in the regulation of eRNA expression. In addition to IL6, these studies indicated that the expression of AZIN1-eRNA and TNFSF8-eRNA were mediated via the ERK-1/2 pathways (Figs. 5 and 6). In the case of p38 inhibitor, our investigations showed a role for this pathway in the LPS-induced expression of SOD2, IL6, TNFSF8-eRNA and ACSL1-eRNA (Figs. 5 and 6). Of relevance, we were unable to demonstrate phosphorylation/activation of JNK-1/2 or an effect of the JNK inhibitors SP600125 (at 10 μM) upon LPS-induced expression of SOD2, IL6 and eRNAs (data not shown). It therefore appears that in addition to NF-κB, the expression of a number of eRNAs are regulated via ERK-1/2 and p38.

3.7. Discussion and conclusions

Advances in sequencing technology have begun to reveal the startling complexity of the human epigenome including the widespread occurrence of enhancer regions, with approximately 400,000 putative enhancers having been identified as part of the ENCODE project [23]. Importantly, it is becoming apparent that the action of these enhancers is dependent upon the production
of eRNAs, an observation supported by the FANTOM project that identified 43,000 bi-directionally transcribed eRNAs across a diverse range of human tissues [16]. Interestingly, dynamic activation and repression of enhancers has been shown to occur upon exposure of immune cells to inflammatory stimuli, suggesting that enhancers have a key role in regulating inflammatory gene expression [13,14,24]. Furthermore, one of the key findings of the FANTOM project was that immune cells such as monocytes, in contrast to terminally differentiated cell types such as epithelial cells, express high relative numbers of eRNAs [16].

However, despite the increasing evidence to suggest the importance of eRNAs in the immune response, little is known about the signalling pathways that regulate their expression. To address this question, we have characterised the mechanisms that regulate 6 eRNAs that are induced in response to LPS [13]. All of these eRNAs overlapped with enhancer regions identified by the FANTOM project [16] and contained numerous binding sites for inflammatory transcription factors. In support of the observation that eRNAs regulate gene expression [8,14], we showed rapid induction of eRNA expression that preceded or correlated with expression of other inflammatory genes upon LPS exposure. Furthermore, distribution studies showed that the majority were located in the nucleus and that their actions might therefore be mediated in cis. Interestingly, the expression of two of the examined eRNAs was not restricted to the nucleus, suggesting that some eRNAs might act in the cytoplasm. Examination of the intracellular signalling pathways indicate that the NF-κB signalling pathway has a central role in regulating LPS-induced eRNA activation, consistent with the reports that NF-κB is required for activation of enhancers in inflammation [14,25]. However, the expression of individual eRNAs were also dependent on ERK-1/2 and p38, implying that transcription and potentially the activation of these enhancers requires multiple transcription factors in addition to NF-κB.

In moving forward it will be necessary to investigate the function of these immune related eRNAs and the mechanisms that regulate their expression. On a genome scale, our previous studies have shown that eRNA expression is correlated with the localised expression of mRNAs. Interestingly, the expression of the nearest mRNAs which includes SLC30A4 (2 fold), AZIN1 (2 fold), SOC3 (14 fold), TNFSF8 (3 fold), MARCKS (7 fold) and ACSL1 (8 fold), were all shown to be induced following LPS exposure. This correlation implies that these eRNAs indeed function to regulate localised gene expression although this would need to be confirmed by eRNA knockdown. Possibly as a result of their nuclear localisation and rapid induction, these eRNAs knockdown studies have proven problematic. However, this situation could be transformed by the recent developments in the area of CRISPRi, which permits inhibition of eRNA transcription rather than the traditional post-transcription approaches involving siRNAs and antisense [26]. Clearly, the other issue is the exact mechanism by which eRNA expression is regulated within the enhancer regions. In addition to NF-κB, this report indicates that transcription factors downstream of ERK-1/2 and p38 such as AP-1 might be also involved in eRNA transcription. As with our studies on p65 (NF-κB), this question can be addressed using ChIP to assess AP-1 binding at eRNA sites and examining the effect of AP-1 knockdown upon eRNA and mRNA expression.

In conclusion, we have characterised the mechanism that regulate the expression of multiple immune-regulated eRNAs and shown that like inflammatory gene expression, this occurs through divergent signalling pathways.

Acknowledgement

Mark A. Lindsay and Benoit Roux are supported by the BBSRC (BB/K006223/1).
References

[1] Medzhitov, R. (2008) Origin and physiological roles of inflammation. Nature 454, 428–435.
[2] Newton, K. and Dixit, V.M. (2012) Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 4, a006049.
[3] O’Neill, L.A.J., Golenbock, D. and Bowie, A.G. (2013) The history of Toll-like receptors – redefining innate immunity. Nat. Rev. Immunol. 13, 453–460.
[4] Stender, J.D. and Glass, C.K. (2013) Epigenomic control of the innate immune response. Curr. Opin. Pharmacol. 13, 582–587.
[5] Blackwood, E.M. and Kadonaga, J.T. (1998) Going the distance: a current view of enhancer action. Science 281, 60–63.
[6] Pennacchio, L.A., Bickmore, W., Dean, A., Nobrega, M.A. and Bejerano, G. (2013) Enhancers: five essential questions. Nat. Rev. Genet. 14, 288–295.
[7] Natoli, G. and Andrau, J.-C. (2012) Noncoding transcription at enhancers: general principles and functional models. Ann. Rev. Genet. 46, 1–19.
[8] Lam, M.T.Y., Li, W., Rosenfeld, M.G. and Glass, C.K. (2014) Enhancer RNAs and regulated transcriptional programs. Trends Biochem. Sci. 39, 170–182.
[9] Melo, C.A. et al. (2013) ERNAs are required for p53-dependent enhancer activity and gene transcription. Mol. Cell 49, 524–535.
[10] Li, W. et al. (2013) Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature 498, 516–520.
[11] Lam, M.T.Y. et al. (2013) Rev-Erbα repress macrophage gene expression by inhibiting enhancer-directed transcription. Nature 498, 511–515.
[12] Moussavi, K. et al. (2013) ERNAs promote transcription by establishing chromatin accessibility at defined genomic loci. Mol. Cell 51, 606–617.
[13] Ilott, N.E. et al. (2014) Long non-coding RNAs and enhancer RNAs regulate the lipopolysaccharide-induced inflammatory response in human monocytes. Nat. Commun. 5, 3979.
[14] Kaikkonen, M.U. et al. (2013) Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol. Cell 51, 310–325.
[15] Heintzman, N.D. et al. (2007) Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39, 311–318.
[16] Andersson, R. et al. (2014) An atlas of active enhancers across human cell types and tissues. Nature 507, 455–461.
[17] Kishimoto, T. (2010) IL-6: from its discovery to clinical applications. Int. Immunol. 22, 347–352.
[18] Tian, L. et al. (1998) Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Am. J. Physiol. 275, C740–7.
[19] Case, A.J. et al. (2011) Elevated mitochondrial superoxide disrupts normal T cell development, impairing adaptive immune responses to an influenza challenge. Free Radic. Biol. Med. 50, 448–458.
[20] Djebali, S. et al. (2012) Landscape of transcription in human cells. Nature 489, 101–108.
[21] Heward, J.A. and Lindsay, M.A. (2014) Long non-coding RNAs in the regulation of the immune response. Trends Immunol. 35, 408–419.
[22] Tripathi, V. et al. (2010) The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol. Cell 39, 925–938.
[23] Dunham, I. et al. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74.
[24] Ostuni, E. et al. (2013) Latent enhancers activated by stimulation in differentiated cells. Cell 152, 157–171.
[25] Teferedege, B., Green, M.R., Guo, Z. and Bass, J.M. (2006) Mechanism of action of a distal NF-kappaB-dependent enhancer. Mol. Cell. Biol. 26, 5759–5770.
[26] Gilbert, L.A. et al. (2014) Genome-Scale CRISPR-mediated control of gene repression and activation. 159, 647–661.